Jenna R.E. Bergerson, M.D., M.P.H.

Primary Immune Deficiency Clinic

Jenna R.E. Bergerson, M.D., M.P.H.

Staff Clinician
Associate Program Director, Allergy-Immunology Fellowship Training Program
Co-Director, Allergy-Immunology Consult Service
Deputy Director, Primary Immune Deficiency Clinic

Contact: For contact information, search the NIH Enterprise Directory.

Specialty(s): Allergy and Immunology
Provides direct clinical care to patients at NIH Clinical Center

  • Diagnosis, natural history, and treatment of primary immune deficiency disorders and disorders of immune dysregulation

Program Description

Dr. Bergerson’s current research and clinical activities focus on seeing patients with a wide variety of primary immune deficiency disorders and primary disorders of immune dysregulation.



M.D., Tulane University School of Medicine

M.P.H., Tulane University

Jenna Bergerson, M.D. is an assistant research physician at NIAID. She has been involved in translational research in primary immune deficiencies and disorders of immune dysregulation since joining the Primary Immune Deficiency Clinic in 2017.

She received her M.D. from Tulane University School of Medicine. She completed a pediatric residency at Rainbow Babies & Children’s Hospital, Case Western University Medical Center in Cleveland, OH, followed by a fellowship in allergy and immunology at The Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Medical Center. She also holds a master of public health degree from Tulane University School of Public Health. She is board certified in pediatrics and allergy-immunology and is a fellow of the American Academy of Allergy, Asthma, and Immunology (AAAAI) and the Clinical Immunology Society (CIS).

At NIH, she serves as the co-director of the Allergy-Immunology Consult Service, as the Deputy Director of the Primary Immune Deficiency Clinic, and on the NIAID inpatient-outpatient working group committee. Her external committee activities include involvement in the membership committee of the Clinical Immunology Society.

Selected Publications

James AE, West L, Schloss K, Nataraj P, Urban A, Hirsch A, Krausz M, Kumar S, Raasch J, Risma K, Church JA, Grimbacher B, Bergerson JRE, Chong H, Freeman AF. Treatment of STAT3-deficient hyper-immunoglobulin E syndrome with monoclonal antibodies targeting allergic inflammation. J Allergy Clin Immunol Pract. 2022 May;10(5):1367-1370.e1.

Nunes-Santos CJ, Koh C, Rai A, Sacco K, Marciano BE, Kleiner DE, Marko J, Bergerson JRE, Stack M, Rivera MM, Constantine G, Strober W, Uzel G, Fuss IJ, Notarangelo LD, Holland SM, Rosenzweig SD, Heller T. Nodular regenerative hyperplasia in X-linked agammaglobulinemia: An underestimated and severe complication. J Allergy Clin Immunol. 2022 Jan;149(1):400-409.e3.

Delmonte OM, Bergerson JRE, Burbelo PD, Durkee-Shock JR, Dobbs K, Bosticardo M, Keller MD, McDermott DH, Rao VK, Dimitrova D, Quiros-Roldan E, Imberti L, Ferrè EMN, Schmitt M, Lafeer C, Pfister J, Shaw D, Draper D, Truong M, Ulrick J, DiMaggio T, Urban A, Holland SM, Lionakis MS, Cohen JI, Ricotta EE, Notarangelo LD, Freeman AF. Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity. J Allergy Clin Immunol. 2021 Nov;148(5):1192-1197.

Delmonte OM, Bergerson JRE, Kawai T, Kuehn HS, McDermott DH, Cortese I, Zimmermann MT, Dobbs AK, Bosticardo M, Fink D, Majumdar S, Palterer B, Pala F, Dsouza NR, Pouzolles M, Taylor N, Calvo KR, Daley SR, Velez D, Agharahimi A, Myint-Hpu K, Dropulic LK, Lyons JJ, Holland SM, Freeman AF, Ghosh R, Similuk MB, Niemela JE, Stoddard J, Kuhns DB, Urrutia R, Rosenzweig SD, Walkiewicz MA, Murphy PM, Notarangelo LD. SASH3 variants cause a novel form of X-linked combined immunodeficiency with immune dysregulation. Blood. 2021 Sep 23;138(12):1019-1033.

Hsu AP, Donkó A, Arrington ME, Swamydas M, Fink D, Das A, Escobedo O, Bonagura V, Szabolcs P, Steinberg HN, Bergerson J, Skoskiewicz A, Makhija M, Davis J, Foruraghi L, Palmer C, Fuleihan RL, Church JA, Bhandoola A, Lionakis MS, Campbell S, Leto TL, Kuhns DB, Holland SM. Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects. Blood. 2019 May 2;133(18):1977-1988.

Arts K, Bergerson JRE, Ombrello AK, Similuk M, Oler AJ, Agharahimi A, Mace EM, Hershfield M, Wouters C, De Somer L, Morren MA, Diego RP, Moens L, Freeman AF, Meyts I. Warts and DADA2: a Mere Coincidence? J Clin Immunol. 2018 Nov;38(8):836-843

Visit PubMed for a complete publication listing.

Training Program

Allergy and Immunology Training Fellowship Program

NIAID offers a three-year training program in allergy and immunology. This program, open to physicians who have completed internal medicine and/or pediatric residency training, is designed to provide trainees with high-quality clinical and research skills that will enable them to successfully pursue careers in academic medicine. 

The NIAID Allergy and Immunology Clinical Fellowship Program is fully accredited by the Accreditation Council for Graduate Medical Education (ACGME). Fellows are eligible to sit for the Board of Allergy and Immunology certification examination after successful completion of the first two years of the program.

Content last reviewed on